Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Isis Pharmaceuticals reports Phase 2 data on ISIS-GCGR Rx


Wednesday, 14 May 2014 07:00am EDT 

Isis Pharmaceuticals Inc:Reports positive data from a Phase 2 study of ISIS-GCGRRxin patients with type 2 diabetes uncontrolled on stable metformin therapy.Patients in the per protocol efficacy population treated with ISIS-GCGRRxachieved statistically reductions in measures of glucose control.Patients treated with ISIS-GCGRRxalso experienced increased plasma GLP-1 levels.To present additional detail from this study as a late-breaking abstract program at the American Diabetes Association 74thScientific Sessions. 

Company Quote

40.48
-0.64 -1.56%
22 Oct 2014